Study Evaluating Vancomycin-Resistant Enterococci in a Hematology Unit
Information source: Wyeth is now a wholly owned subsidiary of Pfizer
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Gram-Positive Bacterial Infections
Intervention: Piperacillin/tazobactam and other β-lactam/β-lactamase (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Wyeth is now a wholly owned subsidiary of Pfizer Official(s) and/or principal investigator(s): Medical Monitor, Study Director, Affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
Summary
To determine the impact of the restriction of the third and forth generation cephalosporins
on the reduction of intestinal colonization or infection with vancomycin-resistant
enterococci (VRE) in a surgical intensive care unit (SICU)
Clinical Details
Official title: Effects on the Emergence and Transmission of Vancomycin-Resistant Enterococci After Changes in Antibiotic Use in a Hematology Unit.
Study design: Observational Model: Case Control, Time Perspective: Longitudinal
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- All patients admitted to or transferred to the SICU.
- Eligible patients will be patients of either sex, 18 years of age or older who are
admitted or transferred to the SICU.
- Provide written informed consent
Exclusion Criteria:
- Patients who have hypersensitivity to penicillin, cephalosporins or beta-lactamase
inhibitors.
- Females who are pregnant and breast feeding
- Any underlying conditions or non-infectious diseases that will be ultimately fatal
within 48 hours.
- Those who have already been participating other clinical study related with
antibiotics.
Locations and Contacts
Incheon 405-760, Korea, Republic of
Ulsan 682-714, Korea, Republic of
Additional Information
Starting date: January 2005
Last updated: March 14, 2007
|